2024 An Eventful Year, page-34

Imho we do not have to have human data from DX-1 trials to get other partners involved with DX-3, but what we do need is money to reactivate DX-3 research, as soon as the GMP for DX-1 is announced as being successful then i'd expect to be multiples of where we are now and then CR and then DX-3 will recommence.....THIS IS WHERE THE APRTNERIING WILL COPME FROM AND FROM A FEW DIFFERING PARTNERS AT THAT..


From the 4c
""The availability of a GLP manufacturing process for PAT-DX3 is expected to facilitate ongoing partnering discussions for this deoxymab and the Company intends to initiate its own production run of PAT-DX3 once it has access to additional capital.""

The end of this year could bring in so much, if the next 7 weeks turns into a success..It will trigger everything else to move forward and i would assume at pace..